International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain

Cancer Immunol Immunother. 2018 Nov;67(11):1809-1813. doi: 10.1007/s00262-018-2240-y. Epub 2018 Sep 4.

Pedro Berraondo^{1

2

3}, Maria Angela Aznar⁴, Elisabeth Perez-Ruiz^{4

5}, Maria Esperanza Rodriguez-Ruiz^{4

6

7}, Eduardo Castañon⁸, Jose Luis Perez-Gracia^{6

7

8}, Ignacio Melero^{9

10

11

12}

¹ Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Edificio CIMA, Avenida Pio XII 55, 31008, Pamplona, Spain. [email protected].
² Navarra Institute for Health Research (IDISNA), Pamplona, Spain. [email protected].
³ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [email protected].
⁴ Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Edificio CIMA, Avenida Pio XII 55, 31008, Pamplona, Spain.
⁵ Division of Medical Oncology, Hospital Costa del Sol, Marbella, Spain.
⁶ Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
⁷ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
⁸ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
⁹ Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Edificio CIMA, Avenida Pio XII 55, 31008, Pamplona, Spain. [email protected].
¹⁰ Navarra Institute for Health Research (IDISNA), Pamplona, Spain. [email protected].
¹¹ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [email protected].
¹² Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. [email protected].

No abstract available

Keywords: Biomarkers; Clinical trial design; Radioimmunotherapy; Synergistic combinations.

MeSH terms